In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Related News Articles

Headline
The Food and Drug Administration Friday cleared for commercial distribution a test to diagnose multiple respiratory viral and bacterial infections in…
Headline
As the Department of Health and Human Services prepares to end the COVID-19 public health emergency on May 11, AHA today recommended the agency take immediate…
Headline
The Food and Drug Administration last week removed the requirement for a positive COVID-19 test result to prescribe Paxlovid to certain adult and…
Headline
The Centers for Medicare & Medicaid Services this week released updated fact sheets for hospitals and other types of Medicare and Medicaid providers…
Headline
Health care providers who received Provider Relief Fund and/or American Rescue Plan Rural payments exceeding $10,000 total between July 1 and Dec. 31, 2021,…
Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…